Metastatic Breast Cancer

Release Date: February 20, 2018
Expiration Date: February 20, 2019

Program Overview
While mortality rates for breast cancer are decreasing, metastatic breast cancer (MBC) remains incurable. This session will review new treatment options based on molecular and genetic information, the level of evidence used to formulate practice guidelines, as well as updates from ASCO 2017. New agents, including PARP inhibitors for those with appropriate mutations, will also be discussed. Clinically-oriented guidelines on the management of MBC were developed by the European Society for Medical Oncology (ESMO) in 2015 with recommendations for the treatment of advanced breast cancer.

Target Audience
The primary audiences for this activity are:

  • Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
  • Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
  • Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
  • Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)


 Joseph Sparano, MD
 Professor of Medicine & Women’s Health
 Albert Einstein College of Medicine
 Associate Chairman, Department of Oncology
 Montefiore Medical Center
 Bronx, NY



Joseph Sparano, MD is Professor of Medicine & Women’s Health at the Albert Einstein College of Medicine; Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center; and Associate Director for Clinical Research at the Albert Einstein Cancer Center.

He also serves as Vice Chair of the ECOG-ACRIN Research Group and Vice Chair of the AIDS Malignancy Consortium. His research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and clinical application biomarkers in breast cancer and other cancers.

Educational Objectives
At the conclusion of this session, participants should be able to demonstrate the ability to:

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of systemic interventions and targeted agents to optimize patient survival
  • Discuss current recommendations for diagnostic testing across multiple tumor types to facilitate treatment selection in patients with breast cancer
  • Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of metastatic breast cancer with attention to cost/benefit and toxicity considerations
  • Evaluate resources to increase patient access and engagement

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Pharmacist Accreditation
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.


Pharmacist Designation
Total number of CE credits made available at this conference is 1.25 hours (0.125 CEUs).

UAN: 0418-9999-18-208-H04-P

A statement of credit will be issued only upon receipt of a completed activity evaluation.

This is an application-based activity.

For questions regarding CME/CE credit, the post-test, evaluation, please email

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology.  Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure Information
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Faculty Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Joseph Sparano, MD: Consultant/Independent Contractor: Roche/Genentech, Celidex, Eli Lilly, Juno, AstraZeneca; Grant/Research Support: Deciphera, Prescient Therapeutics; Shareholder: Metastat

Non-faculty Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene

Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte

FDA Disclosure
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 50% or better, and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.  Participant is allowed to take the post-test multiple times.

Privacy Policy
Click here to view our privacy policy.


Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology


This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit